OSE Immunotherapeutics Announces Procedures for Virtual Combined General Meeting
Regulatory News:
OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE) (Paris:OSE) announces the procedures for participating to the Combined General Meeting, to be held on June 24, 2021 at 2:30 p.m. CET.
As indicated in the press release dated May 19, 2021, the Combined General Meeting of June 24, 2021, will be held by live webcast, without the physical presence of shareholders or other persons usually eligible to attend pursuant to the provisions of the the order published on 25 March 2020 extended and amended by order no. 2020-1497 of 2 December 2020, decree no. 2020-418 of 10 April 2020 extended and amended by decree no. 2020-1614 of 18 December 2020 and decree no. 2021-255 of 9 March 2021.
This clinical trial will be sponsored and conducted by the Italian Oncology Foundation FoRT and supported by Bristol Myers Squibb and OSE Immunotherapeutics. The study will explorethe strategy
(1)
First-in-human study evaluating CoVepiT, a multi-variant T cell COVID-19 vaccine for people at risk and vulnerable populations.
CoVepiT is a peptide-based vaccine aiming to induce CD8+T-cell-mediated immune response against 11 different proteins of SARS-CoV-2 virus to provide a long-term cellular immunity with memory T cells.
Phase 1 study expected to read-out in September 2021.
Regulatory News:
OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE) today announced that the first healthy volunteer has been enrolled and dosed in the Phase 1 clinical trial evaluating its COVID-19 vaccine, named CoVepiT.
This Phase 1 clinical trial is evaluating the safety, reactogenicity and immunogenicity of two dose regimen of CoVepiT in 48 healthy adult volunteers, previously vaccinated or not by an authorized COVID-19 vaccine (NCT04885361).
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Cue Biopharma to Present at the 2021 Frontiers in Cancer Immunotherapy Conference
Cue Biopharma, Inc.May 6, 2021 GMT
CAMBRIDGE, Mass., May 06, 2021 (GLOBE NEWSWIRE) Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient’s body, announced today it will give a poster presentation at the New York Academy of Sciences 2021 Frontiers in Cancer Immunotherapy meeting, which is being held virtually from May 12-14, 2021. The presentation will highlight clinical and preclinical data supporting the mechanism of action (MOA) for the Immuno-STAT™